Track buserelin in Peptimes™
Buserelin is a synthetic peptide analog of luteinizing hormone-releasing hormone (LHRH, also called GnRH), with the formula C60H86N16O13. (Source: FDA's substance registry (GSRS).)
Is buserelin FDA-approved?
Not in the US. Drugs@FDA lists no application with buserelin as an active ingredient. Canada lists Suprefact as a marketed prescription medicine, but that doesn't apply in the US.
Buserelin
Also: Suprefact, Suprecur, buserelin acetate, HOE 766
- Status label in the Peptimes Library
- Approved outside the US
- Routes in Peptimes
- Subcutaneous
- Updated
- 1 Nov 2026
US regulatory status
What studies have looked at
Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.
- In humans
In a 1-year randomised trial in 140 men with painful metastatic prostate cancer, buserelin, estrogens and orchiectomy showed no significant differences in testosterone suppression or survival.
Source: PMID 8908651, checked 1 Nov 2026
How to track it in Peptimes
Add buserelin in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Approved outside the US”. In the US it is not FDA-approved.
- Logging: the amount you took and how you feel.
- Injection sites: each dose records the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell buserelin or any other compound.
More sources
- Health Canada, Drug Product Database, SUPREFACT, DIN 02225166, checked 1 Nov 2026: buserelin (as buserelin acetate) subcutaneous solution, prescription, status “Marketed”.
- FDA, Drugs@FDA, checked 1 Nov 2026: no application lists buserelin as an active ingredient.
- FDA, Global Substance Registration System, Buserelin, checked 1 Nov 2026: its formula and its description as an LHRH analog.